Three-Year Experience with 4-Site Intradermal Booster Vaccination with Rabies Vaccine for Postexposure Prophylaxis

• Published in: Clinical infectious diseases Vol. 33; no. 12; pp. 2085 - 2087
• Main Authors: Tantawichien, Terapong, Tantawichien, Thanphet, Supit, Chalida, Khawplod, Pakamatz, Sitprija, Visith
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 15-12-2001; University of Chicago Press
• Subjects: Adolescent; Adult; Antibodies; Biological and medical sciences; Brief Reports; Chemoprevention; Diploidy; Dosage; Human viral diseases; Humans; Immunization; Immunization, Secondary; Incidence; Infectious diseases; Injections, Intradermal; Injections, Intramuscular; Inoculation; Medical sciences; Rabies; Rabies - epidemiology; Rabies - prevention & control; Rabies vaccines; Rabies Vaccines - administration & dosage; Rabies Vaccines - adverse effects; Rabies virus; Thailand - epidemiology; Vaccination; Viral diseases; Viral diseases of the nervous system; World Health Organization; Thailand; Human; Nervous system diseases; Booster vaccination; Exposure; Vaccine; Intradermal administration; Rabies virus; Infection; Virus; Prevention; Immunoprophylaxis; Mononegavirales; Rhabdoviridae; Efficiency; Viral disease; Rabies; Lyssavirus
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1086/338155

For booster vaccination of previously immunized persons with potential exposure to rabies, the World Health Organization recommends 2 doses of cell-culture vaccine administered intramuscularly or intradermally on days 0 and 3. We believe that four 0.1-mL intradermal booster doses given on a single day could be used at no risk to the recipient. We studied use of a single booster vaccination on day 0 followed by four 0.1-mL intradermal doses of cell-culture rabies vaccines, and we determined that this is a safe, convenient, and economical regimen for postexposure treatment of previously vaccinated individuals.